Table 1.
The list of genes that are subject to dual regulation by 4OHT and TCDD
| Gene | Fold change TCDD vs. vehicle | Fold change 4OHT vs. vehicle in GSE848 | |
|---|---|---|---|
| Genes coordinatelyregulated | |||
| CYP1A1 | Cytochrome P450, family 1, subfamily A, polypeptide 1 | 118.6 | 57.2 |
| CYP1B1 | Cytochrome P450, family 1, subfamily B, polypeptide 1 | 12.2 | 20.2 |
| RAP2A | RAP2A, member of RAS oncogene family | 2.1 | 6.8 |
| TCF7L2 | Transcription factor 7-like 2 (T-cell specific, HMG-box) | 1.9 | 5.7 |
| PCDH8 | Protocadherin 8 | 2.4 | 5.7 |
| ME1 | Malic enzyme 1, NADP(+)-dependent, cytosolic | 2.1 | 4.4 |
| DRD1 | Dopamine receptor D1 | 2.8 | 4.2 |
| VIPR1 | Vasoactive intestinal peptide receptor 1 | 3.5 | 3.2 |
| SLC7A5 | Solute carrier family 7 (cationic amino acidtransporter, y+ system), member 5 | 2.2 | 3.0 |
| FLJ13305 | Hypothetical protein FLJ13305 | −1.9 | −3.0 |
| FN1 | Fibronectin 1 | −1.7 | −3.1 |
| CDH11 | Cadherin 11, type 2, OB-cadherin (osteoblast) | −2.4 | −3.1 |
| ASCL1 | Achaete-scute complex homolog 1 (Drosophila) | −3.4 | −3.3 |
| SVIL | Supervillin | −1.8 | −3.7 |
| COL4A6 | Collagen, type IV, α 6 | −1.6 | −3.9 |
| ADA | Adenosine deaminase | −1.6 | −4.2 |
| SLC1A1 | Solute carrier family 1 (neuronal/epithelial highaffinity glutamate transporter, system Xag), member 1 | −2.6 | −4.7 |
| HSPA2 | Heat shock 70 kDa protein 2 | −1.7 | −5.5 |
| Genes regulated inoppositedirections | |||
| SELL | Selectin L (lymphocyte adhesion molecule 1) | 3.0 | −3.2 |
| MALL | Mal, T-cell differentiation protein-like | 1.7 | −3.2 |
| B4GALT1 | UDP-Gal:βGlcNAc β 1,4-galactosyltransferase, polypeptide 1 | 1.7 | −3.3 |
| C20orf194 | Chromosome 20 open reading frame 194 | 1.6 | −3.3 |
| SLC9A7 | Solute carrier family 9 (sodium/hydrogenexchanger), member 7 | 1.6 | −3.4 |
| KCNN4 | Potassium intermediate/small conductancecalcium-activated channel, subfamily N, member 4 | 2.4 | −3.7 |
| TFAP2A | Transcription factor AP-2 α (activatingenhancer-binding protein 2 α) | 2.0 | −3.8 |
| SPTBN1 | Spectrin, β, nonerythrocytic 1 | 1.6 | −8.2 |
| CALCR | Calcitonin receptor | −2.7 | 6.4 |
| RASGRP1 | RAS guanyl-releasing protein 1 (calcium andDAG-regulated) | −5.5 | 5.3 |
| MYBL1 | v-myb Myeloblastosis viral oncogene homolog(avian)-like 1 | −11.9 | 5.0 |
| FRK | Fyn-related kinase | −1.6 | 4.4 |
| FLJ13236 | Hypothetical protein FLJ13236 | −1.5 | 3.9 |
| SEMA3C | Sema domain, Ig domain (Ig), short basic domain, secreted, (semaphorin) 3C | −1.5 | 3.8 |
| FOS | v-fos FBJ murine osteosarcoma viral oncogenehomolog | −2.4 | 3.8 |
| RHOBTB1 | ρ-related BTB domain containing 1 | −1.6 | 3.7 |
| CDC2 | Cell division cycle 2, G1 to S and G2 to M | −2.4 | 3.6 |
| IGFBP4 | IGF-binding protein 4 | −2.0 | 3.4 |
| PDZK1 | PDZ domain containing 1 | −6.4 | 3.4 |
These genes are regulated by 8-h treatment by 4OHT by more than ±3 fold in the GSE848 dataset and are significantly regulated by TCDD with a fold change of more than ±1.5 fold. The data from the probesets that passed the selection criteria are reported. Significance criteria are described in Materials and Methods. In cases when multiple probesets representing the same gene passed selection, the average fold change is provided.